News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellular Dynamics International Launches MyCellâ„¢ Services



6/7/2012 10:57:52 AM

MADISON, Wis., June 7, 2012 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI), the world's largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell Services. These services include novel iPS cell line reprogramming, genetic engineering and differentiation of iPS cells into commercially available iCell® terminal tissue cells (for example, heart or nerve cells).

"CDI's mission is to be the top developer and manufacturer of standardized human cells in high quantity, quality and purity and to make these cells widely available to the research community. Our MyCell Services provide researchers with unprecedented access to the full diversity of human cellular biology," said Bob Palay, CDI Chief Executive Officer. "The launch of MyCell Services furthers CDI founder and stem cell pioneer Jamie Thomson's vision to enable scientists worldwide to easily access the power of iPSC technology, thus driving breakthroughs in human health."

Over the past 2 years, CDI has launched iCell Cardiomyocytes, iCell Neurons and iCell Endothelial Cells for human biology and drug discovery research. MyCell Services leverage CDI's prior investment in building an industrial manufacturing platform that can handle the parallel production of multiple iPSC lines and tissue cells, manufacturing billions of cells daily.

Chris Parker, CDI Chief Commercial Officer, commented, "Not all studies requiring human cells can be accomplished by using cells from a limited set of normal, healthy donors. Researchers may need iPS cells or tissue cells derived from specific ethnic or disease populations, and MyCell Services enable them to take advantage of our deep stem cell expertise and robust industrial manufacturing pipeline to do so. Previously, scientists had to create and differentiate iPS cells themselves. Such activities consume significant laboratory time and resources, both of which could be better applied to conducting experiments that help us better understand human biology. CDI's MyCell Services enable scientists to re-direct those resources back to their experiments."

CDI pioneered the technique to create iPS cells from small amounts of peripheral blood, although iPS cells can be created from other tissue types as well. Additionally, CDI's episomal reprogramming method is "footprint-free," meaning no foreign DNA is integrated into the genome of the reprogrammed cells, alleviating safety concerns over the possible use of iPS cells in therapeutic settings. These techniques have been optimized for manufacture of over 2 billion human iPS cells a day, and differentiated cells at commercial scale with high quality and purity to match the research needs.

Modeling Genetic Diversity

CDI has several projects already underway using MyCell Services to model genetic diversity of human biology. The Medical College of Wisconsin and CDI received a $6.3M research grant from the National Heart, Lung, and Blood Institute (NHLBI), announcedJuly 2011, for which CDI's MyCell Services will reprogram an unprecedented 250 iPS cell lines from blood samples collected from Caucasian and African-American families in the Hypertension Genetic Epidemiology Network (HyperGEN) study. In addition, MyCell Services will differentiate these iPS cells into heart cells to investigate the genetic mechanisms underlying Left Ventricular Hypertrophy, an increase of the size and weight of the heart that is a major risk factor for heart disease and heart failure.

Researchers are also using CDI's MyCell Services to generate iPS cells and liver cells from individuals with drug induced liver injury (DILI), toward an eventual goal of identifying genetic factors linked to idiosyncratic liver toxicity. "The most problematic adverse drug event is sudden and severe liver toxicity that may occur in less than one in one thousand patients treated with a new drug, and thus may not become evident until the drug is marketed. This type of liver toxicity is not predicted well by usual preclinical testing, including screening in liver cultures derived from random human donors," said Paul B. Watkins, M.D., director of with The Hamner - University of North Carolina Institute for Drug Safety Sciences. "The ability to use iPS cell technology to prepare liver cultures from patients who have actually experienced drug-induced liver injury, and for whom we have extensive genetic information, represents a potential revolution in understanding and predicting this liability."

Screening Human Disease

While most diseases are multi-systemic, focus typically centers on only one organ system. For example, congenital muscular dystrophy (CMD) is a group of rare genetic diseases with a focus on skeletal muscle, yet other systems, including heart, eye, brain, diaphragm and skin, can be involved. Understanding the molecular mechanisms underlying complex disease phenotypes requires access to multiple tissue types from a single patient. While some systems are readily accessible for taking a biopsy sample, for example skin, other organs are not.

Cure CMD, a nonprofit organization focused upon promoting CMD research, treatments and clinical trials, with additional support from The Kettering Family Foundation, has utilized CDI's MyCell Services to create iPS cell lines from CMD patients, with the eventual goal of manufacturing iPS cell-derived cardiomyocytes and neurons. Dr. Anne Rutkowski, Cure CMD Chairman, stated, "Translation of hits from HTS drug screens using hundreds of patient-derived iPS cell lines in the organ cell of interest may revolutionize treatment discovery for rare diseases. While a carefully validated, targetable mechanism is needed, these types of screens can substantially decrease overall costs as iPS cells are renewable resources, expediting possible treatment discovery and identifying epigenetic disease modifiers to develop more homogeneous cohorts for clinical trials. We believe the development of iPS cell lines across the CMDs will support forward momentum and provide scientists with additional resources to study these diseases."

MyCell Services were also used in recently published research by David Gamm, PhD, Assistant Professor of Ophthalmology and Visual Sciences in the UW School of Medicine and Public Health. For this study, CDI reprogrammed iPS cells from a standard blood draw from patients with retinitis pigmentosa, a group of genetic defects that causes blindness. Gamm's lab then successfully differentiated the iPS cells into retinal cells for further study.

CDI will formally introduce MyCell Services at the International Society for Stem Cell Research (ISSCR) 10th Annual Meeting June 13-16, 2012, in Yokahama, Japan.

About Cellular Dynamics International, Inc.
Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells from any individual's stem cell line in industrial quality, quantity and purity. CDI is accelerating the adoption of pluripotent stem cell technology, adapting its methods to fit into standard clinical practice by the creation of individual stem cell lines from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.

SOURCE Cellular Dynamics International, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES